http://www.novartis.com 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml 2010-04-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml 2010-01-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml 2009-10-23T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1349636.shtml Disclaimer 2009-10-22T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1349248.shtml Basel, October 22, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased with our strong underlying performance, led by the momentum of our Pharmaceuticals business, outpacing the competition and benefiting from innovative product growth rejuvenating the portfolio. Our investments in R&D show excellent results, with many key approvals in 2009, most notably the anti-cancer therapy Afinitor and the biotechnology medicine Ilaris. Deliveries of H1N1 pandemic flu vaccines are underway as Novartis works at full capacity to meet public health demands. The Sandoz generics business also made good progress, coupled with a turnaround in the US. We expect record full-year underlying results based on the significant progress to date in 2009. 2009-09-17T22:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1342100.shtml Basel, September 17, 2009 - The US Food and Drug Administration (FDA) has approved Valturna® (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure[2]. This is the first approval for Valturna, which is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or angiotensin receptor blocker (ARB) monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals[1]. 2009-07-21T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329924.shtml Basel, July 21, 2009 - The US Food and Drug Administration (FDA) has approved Tekturna HCT® (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tekturna HCT is a single-pill combination of Tekturna® (aliskiren), the first and only approved direct renin inhibitor[1], and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high blood pressure medications[5]. 2009-07-16T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329090.shtml Basel, July 16, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased that our pharmaceuticals business continues to deliver double-digit underlying growth, driven by the strong momentum of our recently launched products. Our pipeline continues to deliver a steady stream of innovative medicines. In the first six months of 2009 we have introduced our new anti-cancer therapy Afinitor in the US and gained first approval for llaris as a new biologic therapy for auto-inflammatory diseases. We are advancing well in our efforts to rapidly produce and commercialize a vaccine against the H1N1 virus, with clinical trials set to begin in July. We continue to expect record underlying results in constant currencies based on innovation and productivity initiatives. 2009-07-08T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1327640.shtml Basel, July 8, 2009 - Rasilez® (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin[9], an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines. 2009-04-23T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329178.shtml 2009-01-28T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1285325.shtml Basel, January 28, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: Thanks to successful innovation and a leading market position of our healthcare business portfolio, Novartis achieved a strong performance in 2008. Pharmaceuticals returned to dynamic growth and gained market share in the second half of the year, while Vaccines and Diagnostics continued its double-digit growth. Recently launched pharmaceutical products contributed USD 2.9 billion in sales in 2008 further rejuvenating our portfolio, and we submitted 14 major new products filings that underpin our innovation power. Organic growth was complemented by several acquisitions and strategic investments, the most important being the acquisition of a 25% share of Alcon. Novartis anticipates another year of record results in 2009, continuing on its path of sustainable growth. 2008-11-11T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1268561.shtml Basel, November 11, 2008 - New clinical data presented today show first-in-class direct renin inhibitor Rasilez® [*] (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1]. 2008-10-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1260877.shtml Basel, October 20, 2008 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: Led by the enhanced performance of Pharmaceuticals in all regions as well as solid sales growth in Vaccines and Diagnostics and productivity gains in Consumer Health, we have achieved strong results in the third quarter of 2008 despite significant volatility in the global economic environment. We are rejuvenating our portfolio as recently launched pharmaceutical products provided USD 2.1 billion in sales to date in 2008 and several novel medicines have been recognized for their benefits to patients with priority review status at the FDA. Also, with a strong new leadership team, Novartis is positioning itself for continued growth and success in a demanding environment. Despite the economic uncertainty in the world markets, Novartis is on track for another year of record results in 2008, continuing to build momentum by focusing on innovation and performance. 2008-09-09T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1249901.shtml Basel, September 9, 2008 - New data show Galvus® (vildagliptin), an oral treatment for type 2 diabetes, is better tolerated and as effective as commonly prescribed anti-diabetic oral medicines, called thiazolidinediones (TZDs), when added to metformin[1]. Patients treated with Galvus did not gain weight, a common side effect of other type 2 diabetes medicines, regardless of their race, body mass index or age[1]. 2008-09-03T12:35:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1248468.shtml Basel, September 3, 2008 - New clinical data analysis confirms that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in obese patients with high blood pressure compared to the diuretic hydrochlorothiazide (HCT) alone[1]. 2008-08-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1239786.shtml Basel, August 4, 2008 - The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT®[*] (valsartan and hydrochlorothiazide) and Exforge® (amlodipine and valsartan), as initial or 'first-line' therapies in patients likely to need multiple drugs to achieve their blood pressure goals. 2008-07-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1236488.shtml Basel, July 17, 2008 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: The growth acceleration in the second quarter of 2008 and our R&D successes, especially in Pharmaceuticals and Vaccines, demonstrate that our strategy is delivering results and that we are heading towards a promising future despite a weak economy. Speed and productivity of operations are improving and growth in most countries is dynamic.